Enzo Biochem Reports Q3 2025 Financial Loss Amid Revenue Decline and Strategic Review Initiatives

Enzo Biochem, Inc. (NYSE: ENZ) - Q3 2025 Financial Overview

For the quarter ending April 30, 2025, Enzo Biochem, Inc. reported significant financial results with several noteworthy developments:

• Revenues: $6.4 million, down 20% from $8.0 million a year earlier.
• Operating Loss: $3.4 million, compared to a loss of $2.0 million in Q3 2024.
• Net Loss: $2.8 million, versus $3.0 million in the same quarter last year. This translates to a basic and diluted loss per share of $0.05.
• Cash and Cash Equivalents: Decreased from $52.4 million to $36.7 million year-over-year.
• Inventories: $5.7 million, reflecting a slight decrease from $6.8 million the previous year.
• Debt: Long-term debt reduced to $129,000 from $189,000.

Positive Aspects:

• Cost of revenues decreased by 12% to $3.8 million, indicating some efficiency improvements.
• Interest income declined less than operating losses, dropping from $726,000 to $384,000 but illustrating better management of cash reserves.
• Foreign exchange gains increased significantly, improving from a $524,000 loss to a $508,000 gain.

Negative Aspects:

• Declining revenues across all geographies due to macroeconomic challenges, including reduced R&D budgets.
• Higher selling, general, and administrative expenses surged to $4.9 million, up 10% year-over-year.
• Accumulated deficit increased to $302.1 million, compared to $294.4 million in the previous fiscal year.

The company remains under pressure as it navigates a declining revenue environment and ongoing legal challenges following a ransomware attack in April 2023, which exposed sensitive data of approximately 2.5 million individuals. In response, Enzo Biochem has faced multiple inquiries and legal actions that may affect its operational costs and reputation.

Strategically, on April 22, 2025, the board initiated a review of strategic alternatives, considering options such as a business combination or a full sale of the company to maximize shareholder value. The last trading day on NYSE was April 17, 2025, following which the stock transitioned to OTCQX under the new ticker ENZB.

Future Outlook: The management is cautiously optimistic about capitalizing on operational efficiencies and potential strategic transactions aimed at repositioning itself in the life sciences sector.